Coverage Areas
China BioPharmaChina rising is an apt description of the entry and presence of China on the world biopharmaceutical stage. China has made biotechnology and healthcare a major funding prerogative in its long term R&D strategy, with the 2009-2011 period seeing a cumulative CNY2.6 billion invested across 223 projects. This 30-fold increase in spending over the past 15 years is being even further accelerated through the National Science Technology Major Program and ancillary funding which increases targeted spending a further 10X to CNY 27.2B. New initiatives focus on infectious disease and disease management, medical devices, instrumentation and diagnostics, agbio and food security, traditional Chinese medicine as a therapeutic platform, and importantly, massive drug discovery innovation. China has been primarily a point for drug and generics manufacturing, but now the concentration is more on earlier stage R&D in order to transform China into a global pharmaceutical powerhouse. China BioPharma Intelligence addresses a strategic market that combines the world’s largest single emerging biopharmaceutical market with one that poses both partnering and competitive threats to established western biopharmas. This service covers the spectrum of technologies and companies that have the potential to shape the landscape for the next decade. Companies looking for the future of BioPharma in China must:
Sample topics covered by Lux Research:
|